Vericiguat

Overview

Vericiguat is a potent guanylate cyclase stimulant under the development of Bayer HealthCare Pharmaceuticals. Direct stimulation of guanylate cyclase is emerging as a potential new approach for the treatment of renal disorders. In Aug 2016, Bayer in collaboration with Merck completed phase-I clinical trials in Coronary artery disease (In adults, In the elderly) in Germany. In Sep 2016, Phase-III clinical trials in Chronic heart failure in Germany, Hungary and Spain was on-going.

Application

Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Inflammation / Immunology | Guanylate Cyclase

Product Information

• Catalog No.: B2693-475341
• CAS No.: 1350653-20-1
• Molecular Formula: C19H16F2N8O2
• Molecular Weight: 426.39
• Purity: 98%
• Storage: -20°C Freezer
• Solubility: Soluble in DMSO

Source

Original product source